Graft Versus Host Disease Treatment Market Research and Forecast by 2032
By 2032, the global Graft Versus Host Disease (GvHD) treatment market is expected to hit US$ 5,655.37 million, with a compounded annual growth rate of 8.3%. The popularity of corticosteroids and combination therapy for GvHD in hematopoietic cell transplant (HCT) patients has contributed to the market's growth, which is projected to be worth $2,547.86 million in 2022, having grown at a rate of 7.8% between 2016 and 2021. While recent advancements in overall survival and acute GVHD severity levels have benefited allogeneic HCT patients, several challenges remain. Jakafi and Rezurock, two newly approved medications, may be more effective than older drugs in preventing and treating chronic GVHD. In December 2021, the US Food and Drug Administration approved Orencia (abatacept) for the treatment of GVHD in both adult and pediatric patients. Orencia, which is also used to prevent autoimmune disorders, targets T-cells, a critical component of acute GVHD, by binding to and modulating one ...